Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates (NCT03674307) | Clinical Trial Compass
RecruitingNot Applicable
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
United States, Canada3,306 participantsStarted 2018-12-01
Plain-language summary
The Canadian Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK) will test the hypothesis that eliminating the regular use of non-invasive screening tests for CAD AFTER waitlist activation is not inferior to regular (i.e., annual) screening for CAD during wait-listing for the prevention of Major Adverse Cardiac Events. Secondary analyses will assess the impact of screening on the rate of transplantation, and the relative cost-effectiveness of screening.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. adults aged 18 years of age or older
✓. Dialysis-dependent kidney failure and currently being assessed for OR active on the kidney transplant waiting list
✓. expected to require further screening for CAD prior to transplantation (by current standard of care);
✓. able to give consent;
✓. anticipated to undergo transplantation more than 12 months from date of enrolment
Exclusion criteria
✕. patients with signs or symptoms suggestive of uncontrolled cardiac disease such as unstable coronary syndromes, decompensated heart failure, uncontrolled arrhythmia, and severe valvular heart disease;
✕. patients who "on-hold" for transplantation due to a medical problem;
Timeframe: The investigators will analyse time to first MACE event for the duration of the trial (60 months), depending on patient's date of transplant. Follow-up will be 12 months posttransplant. Maximum follow-up is 72 months.